Investigating plasma metabolites and their relationship to early breast cancer
The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
This study is trying to see if certain substances in the blood can help identify breast cancer early and improve treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06698679 on ClinicalTrials.gov |
What this trial studies
This observational study explores the relationship between plasma metabolites and breast cancer to identify potential biomarkers for risk assessment and treatment efficacy. By analyzing plasma samples from both breast cancer patients and healthy controls, the study aims to uncover metabolic changes associated with the disease. The research incorporates clinical data, including cancer stage and treatment outcomes, to enhance understanding of how these metabolites correlate with prognosis. The ultimate goal is to establish a standardized metabolic profile that can aid in personalized therapy for breast cancer patients.
Who should consider this trial
Good fit: Ideal candidates include women with histologically confirmed breast cancer who have not received prior treatment, as well as healthy women without malignancies.
Not a fit: Patients with distant metastases or those with other malignant tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of biomarkers that improve early detection and treatment strategies for breast cancer.
How similar studies have performed: Other studies have shown promise in using metabolomics for cancer diagnosis and treatment, indicating a growing interest in this area, though this specific approach may be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cohort 1 Control Group: women without breast cancer or other malignancies. Case Group: patients with histologically confirmed carcinoma in situ or invasive breast cancer; no prior treatment; no distant metastasis; and not associated with other malignant tumor diseases. * Cohort 2 Pathologically diagnosed as breast cancer; Treatment niave patients; To receive standard neoadjuvant therapy; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) . * Cohort 3 Patients who have been discharged after breast cancer treatment. Exclusion Criteria: * Histologically undiagnosed breast cancer. Breast cancer with distant metastases. Combined with other malignant tumors. Participants must not have participated in other clinical trials within the past month, unless those trials are observational or non-interventional in nature.
Where this trial is running
Shenyang, Liaoning
- Shengjing Hospital of China Medical University — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Study coordinator: Liu Hua, Ph. D
- Email: 20242027@cmu.edu.cn
- Phone: 15140067366
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.